[Federal Register Volume 59, Number 2 (Tuesday, January 4, 1994)]
[Notices]
[Page 308]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-39]


[[Page Unknown]]

[Federal Register: January 4, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

MEDWATCH Conference on Drug and Device-induced Disease: 
Developing a Blueprint for the Future; Notice of Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
Commissioner's MEDWATCH Conference on Drug and Device-Induced Disease: 
Developing a Blueprint for the Future. The conference is co-sponsored 
by FDA and the American Medical Association (AMA) in cooperation with 
the following organizations: American Association of Colleges of 
Nursing, American Association of Colleges of Pharmacy, American 
Association of Dental Schools, American Dental Association, American 
Hospital Association, American Nursing Association, American Society of 
Clinical Pharmacology and Therapeutics, American Society of Hospital 
Pharmacists, Association of American Medical Colleges, and the Council 
on Education in Clinical Pharmacology and Therapeutics.

DATES: The conference will be held on January 21, 1994, from 8:30 a.m. 
to 5 p.m., and January 22, 1994, from 8:30 a.m. to 12:30 p.m.

ADDRESSES: The conference will be held at the Stouffer Mayflower Hotel, 
1127 Connecticut Ave. NW., Washington, DC 20036. Registration is 
required.

FOR FURTHER INFORMATION CONTACT: Mary Pat Couig, Office of Health 
Affairs (HFY-40), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-443-5470. For registration call the American 
Medical Association at 1-800-621-8335.

SUPPLEMENTARY INFORMATION: Drug and device-induced diseases are serious 
health problems. It is estimated that 2 to 10 percent of all 
hospitalizations are a result of serious adverse events. The purpose of 
this conference is to develop recommendations on ways to heighten 
health professionals' awareness of the extent and spectrum of drug and 
device-induced disease and to break down barriers to the discovery and 
reporting of important adverse events to FDA and manufacturers by: (1) 
Strengthening undergraduate curricula, (2) enhancing postgraduate 
training, and (3) building user-friendly reporting mechanisms for 
health professionals.
    David A. Kessler, Commissioner of Food and Drugs, and James S. 
Todd, Executive Vice President of the AMA, will be the keynote 
speakers.
    The conference should be of interest to the following groups: 
Practicing health professionals, health professional organizations, 
health professions educators (undergraduate and graduate), health 
professionals of State health departments, regulatory and safety 
surveillance professionals, and hospital personnel (e.g, risk managers/
quality assurance personnel and members of Pharmacy and Therapeutics 
Committees).
    This is a participatory conference. Recommendations from the 
breakout sessions will be presented on the second day of the conference 
and their implementation discussed at the final panel discussion.

    Dated: December 23, 1993.
David A. Kessler,
Commissioner of Food and Drugs.
[FR Doc. 94-39 Filed 1-3-94; 8:45 am]
BILLING CODE 4160-01-F